Veno-Venous ECMO (VV ECMO) is a form of extracorporeal membrane oxygenation used to provide respiratory support for patients with severe acute respiratory distress syndrome (ARDS). ARDS is a condition characterized by severe hypoxemia (low oxygen levels in the blood), respiratory failure, and pulmonary edema (fluid buildup in the lungs), which can be caused by a variety of conditions, including pneumonia, sepsis, trauma, and aspiration.

In VV ECMO, blood is drained from a large vein, oxygenated outside the body, and then returned to a vein, bypassing the lungs and providing oxygenation and carbon dioxide removal, thereby allowing the lungs to rest and heal. It is typically used when conventional ventilatory support (like mechanical ventilation) is insufficient to maintain adequate oxygen levels and carbon dioxide removal, especially in severe cases of ARDS.

Why VV ECMO for ARDS?

The goal of VV ECMO in ARDS is to provide temporary support for patients when their lungs are not able to provide adequate gas exchange on their own. This allows the lungs to "rest" and heal, while the ECMO machine takes over the critical functions of oxygenating the blood and removing carbon dioxide.

Indications for VV ECMO in ARDS

VV ECMO is typically considered in patients with ARDS who meet certain criteria, often after other treatment options have been exhausted:

1. Severe Hypoxemia (Refractory Hypoxemia):
• PaO2/FiO2 ratio < 100 despite optimal mechanical ventilation and high levels of positive end-expiratory pressure (PEEP), or when the patient is unable to maintain adequate oxygenation despite maximum ventilator support.
• Severe hypoxia (e.g., PaO2 < 60 mmHg with FiO2 ≥ 0.9) that persists despite aggressive mechanical ventilation, including prone positioning and paralytics.
2. Hypercapnic Respiratory Failure:
• Severe hypercapnia (high carbon dioxide levels) that does not resolve with mechanical ventilation, which can occur when the ventilator settings are unable to remove enough carbon dioxide, leading to acidosis.
3. Lung Protective Ventilation Strategies Are Inadequate:
• When lung-protective strategies (i.e., low tidal volume ventilation) are insufficient to manage ARDS, and the patient’s ventilator settings lead to high plateau pressures or barotrauma, VV ECMO can provide a means of reducing ventilator-associated lung injury (VILI) by unloading the lungs.
4. Persistent Respiratory Acidosis:
• Acid-base imbalance (acidosis) that does not improve despite appropriate treatment and mechanical ventilation, which can lead to systemic complications.
5. Failure to Respond to Conventional Therapies:
• When conventional therapy, including high-flow oxygen, non-invasive ventilation, intubation, and mechanical ventilation is not successful, VV ECMO can be used as a rescue therapy.
6. Reversible Underlying Cause:
• The underlying cause of ARDS should ideally be reversible (e.g., pneumonia, sepsis, aspiration), as VV ECMO is a temporary measure to allow time for the lungs to heal.

How VV ECMO Works

VV ECMO is designed to provide respiratory support rather than circulatory support, unlike Veno-Arterial (VA) ECMO, which also supports heart function. In VV ECMO, the focus is on facilitating gas exchange (oxygenation and CO2 removal), thereby relieving the lungs from the stress of mechanical ventilation.

VV ECMO Circuit Components:

1. Venous Cannulation:
• Blood is drained from the venous system (typically the femoral vein or internal jugular vein) using a cannula. The blood is removed from the body via centrifugal pump and flows through the ECMO circuit.
2. Oxygenator:
• The blood passes through an oxygenator, where it is oxygenated and carbon dioxide is removed. This process mimics the function of the lungs.
3. Venous Return:
• The oxygenated blood is then returned to the venous circulation, usually through a cannula in the internal jugular vein, subclavian vein, or femoral vein. Since it remains in the venous system, the oxygenated blood travels through the heart to the systemic circulation, where it is distributed to the tissues.
4. Pressure and Flow Control:
• The ECMO pump ensures that the blood flow through the circuit is sufficient to maintain adequate oxygenation while ensuring that the lungs receive the necessary rest to recover from ARDS.

Benefits of VV ECMO for ARDS

1. Lung Rest and Healing:
• VV ECMO reduces the workload of the lungs, allowing them to heal while the ECMO machine performs gas exchange. This is particularly important in ARDS, where the lungs are inflammatory, edematous, and damaged, making them less efficient at oxygenating blood and removing carbon dioxide.
2. Prevention of Ventilator-Induced Lung Injury (VILI):
• By providing extracorporeal gas exchange, VV ECMO reduces the need for high tidal volumes and high airway pressures, which can cause barotrauma, volutrauma, and atelectrauma in the lungs during mechanical ventilation.
3. Improved Oxygenation:
• VV ECMO can correct severe hypoxemia and hypercapnia that does not respond to conventional ventilation, allowing better tissue oxygenation while waiting for the lungs to recover.
4. Bridge to Recovery:
• It serves as a bridge to recovery for patients with reversible ARDS, offering time for the underlying condition to resolve (e.g., infection treatment, resolution of pulmonary edema) and allowing lung healing.
5. Allows for Protective Ventilation:
• VV ECMO enables the use of lung-protective ventilation strategies, which prioritize using low tidal volumes and lower pressures. This can minimize the risk of additional lung injury during the recovery phase.

Challenges and Risks of VV ECMO for ARDS

1. Bleeding Complications:
• Patients on ECMO require anticoagulation to prevent clot formation in the circuit. This increases the risk of bleeding complications, including cannulation site bleeding, gastrointestinal bleeding, and intracranial hemorrhage.
2. Infection:
• As with all ECMO support, the risk of infection is a concern, particularly in critically ill patients who may have multiple invasive lines and are in prolonged hospital stays. Infection can occur at the cannulation sites or in the ECMO circuit itself.
3. Vascular Complications:
• Cannulation for VV ECMO can lead to vascular injury, thrombosis, or limb ischemia, particularly if the cannula is placed in large veins (e.g., femoral vein) for extended periods.
4. Organ Dysfunction:
• Long-term use of ECMO can contribute to multi-organ failure, especially in the kidneys, liver, and lungs, particularly if there is underlying sepsis or poor perfusion. In addition, renal failure and liver dysfunction may occur as a result of poor perfusion or the stress of ECMO support.
5. Technical Challenges:
• VV ECMO requires constant monitoring and adjustments to the flow rate, oxygenation, and ventilation settings. Issues such as pump failure, clot formation in the circuit, or oxygenator malfunction may occur, requiring rapid intervention.
6. Duration of ECMO Support:
• ECMO is typically considered a temporary solution. Prolonged use of ECMO beyond a few days may be associated with worsened outcomes and increased risk of complications, such as infection or organ failure.

Outcomes and Prognosis

• Survival Rates: The prognosis of VV ECMO in ARDS depends on several factors, including the severity of ARDS, the underlying cause of the condition (e.g., infection, trauma), and how well the patient responds to ECMO therapy. Studies have shown that early initiation of ECMO may lead to better outcomes compared to delayed initiation. The overall survival rate varies, but in patients with reversible causes of ARDS, the survival rate with ECMO is generally favorable.
• Lung Recovery: The success of VV ECMO depends on the reversibility of the lung injury. If the patient’s underlying condition improves (e.g., infection resolves), the lungs may recover, allowing ECMO to be weaned. However, in cases of irreversible lung damage, patients may require further interventions, such as lung transplantation.

Conclusion

VV ECMO is a critical life-saving therapy for patients with severe ARDS who are not responding to conventional mechanical ventilation. By providing extracorporeal respiratory support, VV ECMO allows the lungs to rest and heal, helping to correct severe hypoxemia and hypercapnia. While it can improve outcomes in ARDS patients with reversible causes, the treatment comes with significant risks, including bleeding, infection, and vascular complications, which require careful management. Early intervention, along with a multidisciplinary approach, is crucial for achieving the best outcomes.